We are live on ! Find out more
LP

LMR Partners Portfolio holdings

AUM $45.4B
1-Year Est. Return 60.68%
This Fund
S&P 500
This Quarter Est. Return
+6.09%
1 Year Est. Return
+60.68%
3 Year Est. Return
+183.94%
5 Year Est. Return
+215.13%
10 Year Est. Return
+663.15%
AUM
$9.01B
AUM Growth
+$2.56B
Cap. Flow
+$1.88B
Cap. Flow %
20.91%
Top 10 Hldgs %
32.68%
Holding
1,271
New
274
Increased
124
Reduced
87
Closed
392

Sector Composition

Rank Sector Weight
1 Financials 8.28%
2 Technology 7.66%
3 Healthcare 5.37%
4 Energy 3.3%
5 Utilities 2.99%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow
TXRH icon
501
Texas Roadhouse
TXRH
$12.7B
$295K ﹤0.01%
+2,631
New +$289K
RRC icon
502
Range Resources
RRC
$9.11B
$293K ﹤0.01%
+9,970
New +$271K
IOVA icon
503
Iovance Biotherapeutics
IOVA
$2.23B
$290K ﹤0.01%
41,211
BKSY.WS icon
504
BlackSky Technology Inc Warrants
BKSY.WS
$938K
$284K ﹤0.01%
1,353,603
+200,000
+17% +$29.8K
IWO icon
505
iShares Russell 2000 Growth ETF
IWO
$14.5B
$284K ﹤0.01%
1,169
AEVAW
506
DELISTED
Aeva Technologies Warrants
AEVAW
$278K ﹤0.01%
2,295,835
BARK.WS
507
DELISTED
BARK Inc Warrants
BARK.WS
$277K ﹤0.01%
1,976,337
+660,073
+50% +$88.7K
NBIX icon
508
Neurocrine Biosciences
NBIX
$17.7B
$274K ﹤0.01%
2,905
LANV.WS
509
DELISTED
Lanvin Group Holdings Warrants
LANV.WS
$269K ﹤0.01%
792,222
ADNWW
510
DELISTED
Advent Technologies Holdings Warrant
ADNWW
$266K ﹤0.01%
3,158,425
ADVWW
511
DELISTED
Advantage Solutions Warrant
ADVWW
$260K ﹤0.01%
1,996,923
-5,397
-0.3% -$518
ACLX
512
DELISTED
Arcellx
ACLX
$257K ﹤0.01%
8,116
-2,092
-20% -$80K
CMPX icon
513
Compass Therapeutics
CMPX
$373M
$257K ﹤0.01%
80,692
-65,481
-45% -$206K
BRDG
514
DELISTED
Bridge Investment Group
BRDG
$256K ﹤0.01%
22,533
+3,278
+17% +$33.4K
KYNB
515
PUT
Kyntra Bio
KYNB
$28.5M
$249K ﹤0.01%
+3,688
New +$1.53M
MUSA icon
516
Murphy USA
MUSA
$11.3B
$246K ﹤0.01%
+791
New +$221K
MVSTW
517
DELISTED
Microvast Holdings Warrants
MVSTW
$242K ﹤0.01%
1,181,416
ITOS
518
DELISTED
iTeos Therapeutics
ITOS
$238K ﹤0.01%
17,972
-94,947
-84% -$1.35M
FRO icon
519
Frontline
FRO
$8.75B
$238K ﹤0.01%
16,376
-616,599
-97% -$9.21M
VRDN icon
520
Viridian Therapeutics
VRDN
$2.13B
$238K ﹤0.01%
10,000
-10,000
-50% -$256K
RSVRW icon
521
Reservoir Media Inc Warrant
RSVRW
$232K ﹤0.01%
155,908
-154
-0.1% -$231
TBLAW
522
DELISTED
Taboola.com Ltd Warrant
TBLAW
$224K ﹤0.01%
561,187
+157,387
+39% +$66.1K
LTCHW
523
DELISTED
Latch, Inc. Warrant expiring 6/4/2026
LTCHW
$218K ﹤0.01%
2,058,534
+1,196,998
+139% +$102K
GRND.WS
524
DELISTED
Grindr Inc. Warrants, each exercisable for one share of Common Stock at an exercise price of $11.50 per share
GRND.WS
$214K ﹤0.01%
306,038
CMAXW
525
DELISTED
CareMax, Inc. Warrant
CMAXW
$212K ﹤0.01%
548,755
+6,300
+1% +$2.76K

Similar funds

LMR Partners's Q2 2023 Portfolio in Review

As of Q2 2023, LMR Partners held 1,271 positions worth $9.01B, up 40% from $6.45B the previous quarter. Its ten largest holdings account for 33% of the portfolio.

LMR Partners deployed $1.88B of net new capital in Q2 2023, opening 274 new positions and adding to 124 existing holdings. Its largest new stake was IVERIC bio, Inc. Common Stock: 2,023,659 shares worth $79.6M.

By sector, the portfolio is most concentrated in Financials at 8.3% of assets, down from 14% a quarter earlier, followed by Technology and Healthcare.

On the sell side, the largest reduction was SPDR Gold Trust, an estimated $96.4M trimmed.

  • LMR Partners's largest Q2 2023 buy was IVERIC bio, Inc. Common Stock: 2,023,659 shares worth $79.6M.
  • LMR Partners added most to Activision Blizzard in Q2 2023, an estimated $50.2M increase.
  • LMR Partners's biggest Q2 2023 reduction was SPDR Gold Trust, cutting an estimated $96.4M.
  • LMR Partners fully exited Shaw Communications Inc. in Q2 2023, selling an estimated $43.2M.
  • LMR Partners's ten largest holdings make up 33% of its $9.01B portfolio in Q2 2023.
  • LMR Partners opened 274 new positions and closed 392 in Q2 2023.
  • LMR Partners's portfolio value rose 40% quarter-over-quarter to $9.01B.

Based on LMR Partners's 13F filing for Q2 2023, filed 14 Aug 2023.